Table 2.
Summary of EuroFlow meetings and their main topics addressed
| City, Country | Dates | Main topics of meeting | |
|---|---|---|---|
| 1 | Salamanca, ES | 6–9 April 2006 |
Harmonization of informed consent forms and procedures List of consensus markers for evaluation of informativity Priority list of novel antibodies to be developed Introduction to multicolor flow cytometry Brainstorming on antibody protocols |
| 2 | Rotterdam, NL | 20–23 September 2006 |
Standardization of instrument setup Choices of fluorochromes for the antibody protocols Introduction to Infinicyt software Development of immunobead assays for fusion gene proteins Preliminary proposals for backbone antibody testing per disease category |
| 3 | Prague, CZ | 25–27 January 2007 |
First test results of BCR-ABL cytometric immunobead assay Final proposal for fluorochrome choices First proposals for choices of backbone markers First design for ALOT and LST |
| 4 | Kiel, DE | 28–30 June 2007 |
First testing results of ALOT and LST and proposal for adjustments First design for PCD panel Confirmation of backbone markers and first proposal for B-, T- and NK-CLPD panels Final proposal for backbone markers for the AML/MDS and T-ALL panels |
| 5 | Lisbon, PT | 22–24 November 2007 |
Fine tuning of ALOT, LST and PCD panels New design of B-, T- and NK-CLPD panels First testing results of BCP-ALL, T-ALL and AML/MDS panels and proposal for adjustment |
| 6 | Paris, FR | 24–26 April 2008 |
Final proposals for the ALOT and PCD panels Fine tuning of BCP-ALL, T-ALL, AML/MDS, T- and NK-CLPD panels First results of standardization of immunostaining protocols Final SOP for instrument settings and compensation |
| 7 | Roosendaal, NL | 25–26 June 2008 |
First proposal for standardized immunostaining protocols Ongoing testing of all panels First results of the testing of the BCR-ABL RUO immunobead assay |
| 8 | Kraków, PL | 2–4 October 2008 |
First results of standardization of FCS and SSC scatter patterns Ongoing testing of all panels BCP-ALL and T-ALL panels ready to be used in prospective routine diagnostic testing versus conventional onsite panels |
| 9 | Schiphol, NL | 14–15 December 2008 | Final proposal for B-CLPD panel |
| 10 | York, UK | 11–13 February 2009 |
Final proposal for standard sample preparation protocol Standard proposal for titration of antibodies First design of SST panel All other panels ready for collecting large series of samples for the EuroFlow database Introduction of multivariate analysis of testing results using the Infinicyt software PML-RARA immunobead assay ready for testing |
| 11 | Salamanca, ES | 14–16 May 2009 |
Collection of samples for reference data files for the EuroFlow database for all panels Final proposal for SST panel Use of EuroFlow panels in routine diagnostics |
| 12 | Schiphol, NL | 22–24 September 2009 | Collection of samples for reference data files for the EuroFlow database for all panels |
| 13 | Lisbon, PT | 14–16 January 2010 | Collection of samples for reference data files for the EuroFlow database for all panels |
| 14 | Salamanca, ES | 14–17 April 2010 |
Collection of samples for reference data files for the EuroFlow database for all panels First design and testing of MRD panels for various disease categories |
| 15 | Hoofddorp, NL | 13–15 October 2010 |
Collection of samples for reference data files for the EuroFlow database for all panels First design and testing of MRD panels for various disease categories |
| 16 | Paris, FR | 13–14 January 2011 | Brainstorm meeting on ALL MRD panels |
| 17 | Lisbon, PT | 20–21 January 2011 | Brainstorm meeting on B-CLPD MRD panels |
| 18 | Leuven, BE | 16–18 March 2011 |
Testing of adjusted MRD antibody panels for various disease categories Collection of samples completed for most EuroFlow panels |
| 19 | Prague, CZ | 5–7 October 2011 |
Discussion on final draft of EuroFlow Antibody Panel manuscript Discussion on results of adjusted MRD antibody panels |
| 20 | Katowice, PL | 21–23 March 2012 | Discussion on results of adjusted MRD antibody panels |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ALOT, acute leukemia orientation tube; BCP, B-cell precursor; BE, Belgium; CLPD, chronic lymphoproliferative disorder; CZ, Czech Republic; DE, Germany; ES, Spain; FR, France; FSC, forward scatter; LST, lymphoid screening tube; MDS, myelodysplastic syndrome; MRD, minimal residual disease; NL, The Netherlands; PCD, plasma cell disorders; PL, Poland; PT, Portugal; RUO, research use only; SOP, standard operating protocol; SSC, sideward scatter; UK, United Kingdom.